文献速递糖尿病

褪黑素损害糖耐量、一相胰岛素分泌及胰岛素反馈抑制,并与MTNR1B糖尿病风险变异交互作用

Melatonin Impairs Glucose Tolerance, First-Phase Insulin Secretion, and Insulin Feedback Inhibition; Interaction With MTNR1B Diabetes Risk Variant.
PubMed 文献 · Diabetes Care · 2026-01-01

OBJECTIVE: Melatonin use quintupled in recent decades. The common melatonin receptor 1B gene (MTNR1B) variant increases risk of type 2 diabetes, raising concerns about melatonin's adverse metabolic effects and highlighting the need for a genotype-based personalized approach.…

要点

  • 褪黑素仅在有MTNR1B风险等位基因的健康人中恶化糖耐量并损害β细胞功能。
  • 机制涉及一相β细胞反应性抑制及胰岛素负反馈失调。
  • 风险携带者使用褪黑素后外源性胰岛素所致低血糖事件消失。

核心结论

  • 褪黑素通过抑制β细胞对葡萄糖的反应性和失调胰岛素负反馈,将褪黑素信号与糖尿病风险联系起来。

研究设计与样本

  • 每名参与者接受5天实验室方案,随机顺序在两天非连续日口服5mg褪黑素或安慰剂。
  • 采用胰岛素修饰静脉葡萄糖耐量试验及最小模型分析评估血糖动态。

主要发现

  • 在风险等位基因携带者中,褪黑素较安慰剂恶化糖耐量11.7%(95%CI 1.0-22.3)并降低早期C肽反应-19.2%(95%CI -33.9至-1.2),Padj<0.05;非携带者无此变化。
  • 在携带者中,褪黑素抑制葡萄糖刺激的一相β细胞反应性40%(95%CI -52.4至-24.3,Padj=0.0003),并延缓胰岛素诱导的二相胰岛素分泌率下降64.3%(95%CI 23.1-119.2,Padj=0.001)。
  • 在携带者中,褪黑素较安慰剂阻止外源性胰岛素诱导的低血糖(0次 vs 7次事件,P=0.001),非携带者无此差异。

临床怎么用

  • 对携带MTNR1B风险等位基因者,处方褪黑素时需评估糖代谢影响。

局限性

  • 仅评估单次5mg褪黑素短期效应,长期影响未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Melatonin use quintupled in recent decades. The common melatonin receptor 1B gene (MTNR1B) variant increases risk of type 2 diabetes, raising concerns about melatonin's adverse metabolic effects and highlighting the need for a genotype-based personalized approach. We aimed to comprehensively characterize the actions of melatonin on glucose homeostasis, including first- and second-phase β-cell responsivity to glucose, β-cell negative feedback by exogeneous insulin, insulin sensitivity, and whether such effects are stronger in MTNR1B G-allele risk carriers compared with noncarriers. RESEARCH DESIGN AND METHODS: Twenty-one healthy participants of European ancestry were studied in a randomized, double-blind, placebo-controlled, crossover trial, including 10 MTNR1B risk carriers and 11 noncarriers. Each participant underwent a highly controlled 5-day laboratory protocol, during which they received 5 mg oral melatonin or placebo in randomized order on two nonconsecutive days. Glycemic dynamics were assessed using insulin-modified intravenous glucose tolerance tests with minimal-model analysis. RESULTS: Melatonin worsened glucose tolerance and reduced early C-peptide responses in risk allele carriers (vs. placebo: 11.7% [95% CI 1.0-22.3] and -19.2% [-33.9 to -1.2], respectively; Padj < 0.05) but not in noncarriers. In carriers, impairments stemmed from a 40% (-52.4 to -24.3; Padj = 0.0003) suppression of glucose-stimulated first-phase β-cell responsivity, along with a slower insulin-induced decline in second-phase insulin secretion rate (64.3% [23.1-119.2]; Padj = 0.001). In carriers, melatonin also prevented exogenous insulin-induced hypoglycemia compared with placebo (zero vs. seven events, P = 0.001), but not in noncarriers. CONCLUSIONS: These findings identify blunted β-cell responsivity to glucose and dysregulated insulin negative feedback as key mechanisms linking melatonin signaling to diabetes risk.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Qian J, Stefanovski D, Andersen PAK, et al. Melatonin Impairs Glucose Tolerance, First-Phase Insulin Secretion, and Insulin Feedback Inhibition; Interaction With MTNR1B Diabetes Risk Variant. Diabetes Care. 2026. PMID: 42346809. doi:10.2337/dc26-0164

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。